Arvinas, Inc. Share Price & Technical Analysis
ARVN · $9.09 (-0.11%)
Healthcare / Biotechnology
$9.09
-0.11%
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-7% return in May, 0% avg return in past 3 year May month.
-20% return in 2026, 12% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 13% | 1% | -18% | -8% | -7% | – | – | – | – | – | – | – | -20% |
| 25 | -10% | 2% | -61% | 37% | 13% | 10% | 0% | 5% | 9% | 17% | 25% | -4% | 44% |
| 24 | 2% | 6% | -12% | -23% | 4% | -20% | 3% | -5% | -5% | 8% | 0% | -26% | -69% |
| 23 | -4% | -7% | -11% | -4% | -17% | 14% | 0% | 15% | -31% | -17% | 38% | 86% | 62% |
| 22 | -13% | -9% | 5% | -19% | -23% | 0% | 27% | -20% | 6% | 10% | -19% | -17% | -72% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$614.53M
P/E ratio
—
52W high
$14.51
52W low
$6.06
Volume
6,12,960
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Arvinas, Inc. share price today?
- Arvinas, Inc. (ARVN) last traded around $9.09 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ARVN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ARVN. Download the app for real-time alerts.
- How can I analyze Arvinas, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.